Researchers of the University of Barcelona (UB) have analyzed, with massive sequencing techniques for the first time, the evolution of the hepatitis A virus with samples from patients. The results, published in the journal EBioMedicine, show the presence of variants of the virus that could escape the effects of the vaccine. The study, led by the Research Group on Enteric Viruses of the UB, in collaboration with Vall d'Hebron Research Institute (VHIR) and the Public Health Agency of Barcelona (ASPB), can have implications in the vaccination policies against the disease.
The article counts on the participation of the lecturers Aurora Sabrià , Albert Bosch, Susana Guix and Rosa Maria Pintó, from the Department of Genetics, Microbiology and Statistics of the Faculty of Biology of the UB.
Hepatitis A is a liver inflammation caused by a virus. Its symptomatology is quite light and can disappear after the first weeks, but in some cases the disease can last for months. Among the most affected groups are men who have risky sexual behaviours with other men (MSM).
This study analyzed samples from MSM patients, both vaccinated and non-vaccinated, who caught the virus during an outbreak of hepatitis A in Barcelona (2016-2018). The objective was to study the evolution of the virus and check whether there are emerging variants that can escape the effects of the vaccine. "We identified antigenic variants in vaccinated and non-vaccinated patients, but only the former increase in number, which suggests the positive selection," says Pintó.
The appearance of the hepatitis A virus antigenic variants could become a threat to public health and could have consequences in the future uses of the current available vaccines. "If we select a variant which escapes the vaccine, this one would stop being effective. The study shows that, in cases such as the occurred one due the lack of vaccines, this can happen," notes the researcher.
In some countries, controlling recent outbreaks of hepatitis A has been blocked by the low coverage of vaccination and lack of vaccines, which made administrations apply restrictions in the doses.
During the outbreak, these restrictions affected especially people in the MSM group. "If a few doses of vaccination are given, or if the common doses were given long ago, or the vaccine is given to patients who caught the virus weeks ago, those variants of the virus that avoid the effects of the vaccine can be selected. This is especially relevant in the MSM group, since the virus dose through risky sexual practises is very high, and circulating antibodies are not enough to neutralize the inoculum or the first produced viruses," says Pintó.
In this sense, researchers recommend giving two doses of the vaccine and, in some situations stated in the publication, they suggest giving additional booster doses.
Apart from specifying the vaccination protocol, the expert states they should "work in order to have easier-to-get vaccines so there are no vaccine shortages and doses do not have to be reduced."
Source: University of Barcelona
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.